[1]
Hunter P, Fryhofer SA, Szilagyi PG. Vaccination of Adults in General Medical Practice. Mayo Clinic proceedings. 2020 Jan:95(1):169-183. doi: 10.1016/j.mayocp.2019.02.024. Epub
[PubMed PMID: 31902413]
[2]
Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, Nelson NP. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2018 Jan 12:67(1):1-31. doi: 10.15585/mmwr.rr6701a1. Epub 2018 Jan 12
[PubMed PMID: 29939980]
[3]
. Hepatitis B vaccines: WHO position paper – July 2017. Releve epidemiologique hebdomadaire. 2017 Jul 7:92(27):369-92
[PubMed PMID: 28685564]
[4]
Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR. Hepatitis B vaccination. Human vaccines & immunotherapeutics. 2015:11(1):53-7. doi: 10.4161/hv.34306. Epub 2014 Nov 1
[PubMed PMID: 25483515]
[5]
Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, Parkinson AJ. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. The Pediatric infectious disease journal. 2004 Jul:23(7):650-5
[PubMed PMID: 15247604]
[6]
Gabbuti A, Romanò L, Blanc P, Meacci F, Amendola A, Mele A, Mazzotta F, Zanetti AR. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine. 2007 Apr 20:25(16):3129-32
[PubMed PMID: 17291637]
[7]
S KRN, Nishanth AN, R S AB, Nivedh K, Syed NH, R RS. Hepatitis B-surface antigen (HBsAg) vaccine fabricated chitosan-polyethylene glycol nanocomposite (HBsAg-CS-PEG- NC) preparation, immunogenicity, controlled release pattern, biocompatibility or non-target toxicity. International journal of biological macromolecules. 2020 Feb 1:144():978-994. doi: 10.1016/j.ijbiomac.2019.09.175. Epub 2019 Oct 25
[PubMed PMID: 31669465]
[8]
Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, La Rosa M, Leonardi S. Hepatitis B vaccine by intradermal route in non responder patients: an update. World journal of gastroenterology. 2014 Aug 14:20(30):10383-94. doi: 10.3748/wjg.v20.i30.10383. Epub
[PubMed PMID: 25132754]
[9]
Cardell K, Akerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. The Journal of infectious diseases. 2008 Aug 1:198(3):299-304. doi: 10.1086/589722. Epub
[PubMed PMID: 18544037]
[10]
Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. Infection control and hospital epidemiology. 1995 Feb:16(2):88-91
[PubMed PMID: 7759824]
[11]
O'Leary ST, Maldonado YA, Byington CL. Update From the Advisory Committee on Immunization Practices. Journal of the Pediatric Infectious Diseases Society. 2017 Sep 1:6(3):215-218. doi: 10.1093/jpids/pix040. Epub
[PubMed PMID: 28903515]
[12]
Swedish Council on Health Technology Assessment. Vaccines to Children: Protective Effect and Adverse Events: A Systematic Review. 2009 Feb:():
[PubMed PMID: 28876765]
[13]
O'leary ST, Maldonado YA, Kimberlin DW. Update From the Advisory Committee on Immunization Practices. Journal of the Pediatric Infectious Diseases Society. 2019 Dec 27:8(6):495-500. doi: 10.1093/jpids/piz058. Epub
[PubMed PMID: 31589289]
[14]
Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, de Perio MA, Reilly M, Byrd K, Ward JW, Centers for Disease Control and Prevention (CDC). CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2013 Dec 20:62(RR-10):1-19
[PubMed PMID: 24352112]
[15]
Constable C, Caplan A. Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: Implications for future vaccines. Vaccine. 2020 Jan 29:38(5):954-962. doi: 10.1016/j.vaccine.2019.11.073. Epub 2019 Dec 13
[PubMed PMID: 31843271]
[16]
Splawn LM, Bailey CA, Medina JP, Cho JC. Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States. Drugs of today (Barcelona, Spain : 1998). 2018 Jul:54(7):399-405. doi: 10.1358/dot.2018.54.7.2833984. Epub
[PubMed PMID: 30090877]
[17]
Hyer R, McGuire DK, Xing B, Jackson S, Janssen R. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. Vaccine. 2018 May 3:36(19):2604-2611. doi: 10.1016/j.vaccine.2018.03.067. Epub 2018 Apr 5
[PubMed PMID: 29628151]